Smart policies to deliver cures to patients
Patients deserve access to the treatments they depend on. That’s why Pfizer and the Ready for Cures community are working to advance smart public policies that could reduce patients’ out-of-pocket costs at the pharmacy counter and improve access to treatments — without stifling scientific innovation that could lead to life-saving cures. Potential solutions to accomplish these goals include the following:
- Support AMR research: Antimicrobial resistance (AMR) among “superbugs” is a leading cause of death around the world. Stopping the spread means investing in innovation to discover groundbreaking treatments. Prevention is key to saving lives. Legislation that incentivizes innovation can help reinvigorate a robust pipeline of new treatments to stop the spread of superbugs. Learn more about AMR.
- Invest in innovative technologies like gene therapy. Gene therapy could allow patients to live without the need for ongoing treatments or the burden of daily disease management. Investments in innovative treatments like gene therapy can help people thrive in every stage of life. Learn more about gene therapy.
- Ensure patients receive the savings they deserve: In the current broken system, insurers and pharmacy benefit managers negotiate billions of dollars in rebates and discounts from pharmaceutical companies. Instead of passing those rebates on to patients, middlemen keep these savings. And it’s only getting worse: Data reveals that insurers and PBMs are siphoning off more profits than ever before. Get the facts and learn how to help patients access healthcare savings.
- Increase the use of biosimilars: Biosimilars are FDA-approved and often offer a lower-cost alternative to biologic therapies that treat challenging diseases like cancer, diabetes, and rheumatoid arthritis. Biosimilars give patients a safe and often lower cost option than their originator biologics. Learn more about biosimilars.
Join the Ready for Cures community to receive updates on how you can help reduce out-of-pocket costs for patients and protect scientific innovation.